Sign in
Taking peoplePhase 2

A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma

Key facts

Who runs it
Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
27 people, planned
Started
29 Sept 2026
Expected to end
31 Dec 2029
Type of study
Interventional
Treatments tested
  • Retlirafusp Alfa Injection
Record updated
13 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Histopathologically confirmed unresectable or metastatic mucosal melanoma
  • Subjects must provide 5 paraffin-embedded tissue sections obtained prior to treatment for immune microenvironment (immune infiltration) scoring
  • The Eastern Cooperative Oncology Group (ECOG) scoring system in the United States has a score range of 0-1
  • No prior systemic therapy. Patients who developed recurrence or metastasis more than 6 months after discontinuation of adjuvant therapy are excluded from this criterion (i.e., such patients are eligible)
  • Presence of at least one measurable lesion according to RECIST 1.1 criteria
  • No history of immunosuppressive drug use within 6 months prior to enrollment
  • Adequate hematologic and organ function, meeting the following laboratory criteria:; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; ii. Platelet count ≥ 100 × 10⁹/L; iii. Hemoglobin > 9.0 g/dL; iv. Serum creatinine ≤ 1.5 × ULN, or creatinine clearance (CrCl) ≥ 40 mL/min; v. AST/ALT ≤ 3 × ULN; vi. Total bilirubin ≤ 1.5 × ULN
  • No active bleeding
  • Urine protein ≤ 1+ or < 1 g/24h
  • Women of childbearing potential must have a negative serum or urine pregnancy test and agree to use adequate contraception (barrier method or oral contraceptives) during the study

Who cannot take part

  • Patients with concurrent other malignancy requiring anti-tumor therapy cannot be enrolled in this study. However, if the malignancy has achieved complete remission for two years or more, and no additional anti-tumor therapy is required during the study period, enrollment may be considered
  • Prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-TGF-β, or other agents targeting T-cell co-stimulatory or immune regulatory pathways
  • Prior treatment with taxanes, platinum-based agents, or anti-angiogenic agents
  • Presence of untreated CNS metastases, or CNS metastases requiring corticosteroids for edema control
  • Tumor invasion of major blood vessels (e.g., carotid artery, aorta), concurrent active ulcer, or history of gastrointestinal bleeding
  • Patients with active autoimmune disease. Note: Patients with vitiligo, type I diabetes mellitus, or hypothyroidism due to Hashimoto's thyroiditis requiring only hormone replacement therapy may be enrolled if there is no obvious evidence of recurrence
  • Patients requiring systemic corticosteroid therapy (> 10 mg prednisone [or equivalent] per day) or other immunosuppressive agents within 14 days after enrollment. Note: Inhaled or topical corticosteroids, or adrenal hormone replacement therapy (> 10 mg prednisone [or equivalent] per day) are acceptable for patients without obvious autoimmune disease
  • History of myocardial infarction or stroke within the past 6 months
  • Positive HIV test or confirmed diagnosis of acquired immunodeficiency syndrome (AIDS)
  • Uncontrolled hypertension, commonly defined as: systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg despite optimized antihypertensive therapy, or requiring ≥ 2 antihypertensive agents without achieving target
  • Patients with a history of severe (≥ G3) immune-related adverse events (irAEs) involving major organs, such as immune-mediated hepatitis, pneumonitis, myocarditis, colitis, or central nervous system toxicity
  • Allergy to the study drug or its components
  • Cardiac arrhythmias requiring pharmacological or device intervention, affecting hemodynamic stability, or posing a risk of sudden death, including but not limited to uncontrolled rapid atrial fibrillation, ventricular tachycardia, atrioventricular block, and QTc ≥ 500 ms
  • Uncontrolled heart failure, defined as NYHA class III-IV, or persistent significant symptoms despite optimized therapy, or recent need for hospitalization or intravenous therapy, or significantly reduced left ventricular ejection fraction (e.g., < 40-50%)
  • Patients who, in the investigator's judgment, are medically, psychologically, or physiologically unable to complete this study or to understand the patient information
  • Presence of unhealed wounds
  • Pregnant or lactating women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a prospective, single-arm, open-label Phase II clinical study. The main purpose of this study is to evaluate the effectiveness of nab-paclitaxel combined with retlirafusp alfa injection and apatinib mesylate in patients with advanced mucosal melanoma.

Read full original descriptionShow less

Participants will receive treatment with nab-paclitaxel combined with retlirafusp alfa injection and apatinib mesylate. Each treatment cycle lasts 3 weeks, and participants will receive a total of 6 cycles. Participants whose disease does not progress after the initial treatment will continue maintenance therapy with apatinib mesylate combined with retlirafusp alfa injection until their disease progresses or they experience intolerable side effects.

After enrollment, participants will undergo safety visits before each dose on Day 1 and Day 21 of each treatment cycle. Tumor imaging assessments will be performed before treatment and after every 2 to 4 cycles of treatment. Clinical response will be evaluated by radiologists according to the RECIST 1.1 criteria.

Researchers will monitor participants for any adverse events throughout the study and will grade the severity of these events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. After treatment is completed, participants will be followed for 12 weeks for safety monitoring, and long-term survival follow-up will continue.

The group in the trial

  • Assigned InterventionsTreatment being tested

    Drug: Nab-paclitaxel Injection Nab-paclitaxel 200 mg/m² IV infusion Q3W Drug: Retlirafusp Alfa Injection Retlirafusp Alfa 1 diluted in 250 mL normal saline IV, administered 30 minutes before chemotherapy, Q3W Drug: Apatinib Mesylate Tablet Apatinib Mesylate 250 mg PO QD Regimen: Nab-paclitaxel + Retlirafusp Alfa + Apatinib Mesylate, Q3W × 6 cycles (combination phase); maintenance: Apatinib Mesylate + Retlirafusp Alfa until disease progression or unacceptable toxicity

    Treatment: Retlirafusp Alfa Injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Single-Arm, Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa Injection and Apatinib Mesylate for Advanced Mucosal Melanoma
Record updated
13 November 2026